Education
About Us
Working with TipRanks
Follow Us
PAVmed Inc (PAVM)
NASDAQ:PAVM
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.13Last Year’s EPS
-1.19Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -10.96%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments, such as a strengthened balance sheet, progress in diagnostic and health platforms, and strategic expansion plans. However, the company still faces challenges, particularly in securing Medicare coverage for Lucid and navigating potential market volatility. Overall, the positives and strategic directions appear to slightly outweigh the uncertainties and dependencies.Company Guidance
During PAVmed's First Quarter 2025 Business Update Conference Call, the company outlined several key metrics and strategic initiatives. Lucid, PAVmed's diagnostic subsidiary, reported a quarterly revenue of $800,000 with a test volume of 3,034, which is at the upper end of their target range. Lucid also bolstered its financial position with a $16.1 million public offering, extending its financial runway well into 2026. Veris Health, another subsidiary, secured financing for the development of an implantable monitor, with an FDA filing targeted for the first half of 2026. PAVmed's balance sheet reflected significant improvements, including a liability reduction of approximately $25 million and an increase in preferred stock. The company's strategic focus includes exploring opportunities in the biopharma space, leveraging its established infrastructure and track record in advancing subsidiaries and conducting clinical trials.Strengthened Balance Sheet
PAVmed significantly strengthened its balance sheet with an underwritten public offering netting $16.1 million, bolstering the balance sheet and extending the runway well into 2026.
Lucid Diagnostics Performance
Lucid reported revenue of $800,000 in the last quarter with a test volume of 3,034, reaching the upper end of the target range of 2,500 to 3,000 tests per quarter.
Veris Health Development
Financing secured to restart development of a key implantable physiologic monitor, with an FDA filing targeted for the first half of 2026.
Strategic Expansion into Biopharma
PAVmed is actively pursuing opportunities to expand into the biopharma space, leveraging its existing infrastructure and track record.
PAVM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PAVM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $0.73 | $0.63 | -13.70% |
Mar 24, 2025 | $0.81 | $0.80 | -1.23% |
Nov 14, 2024 | $1.02 | $1.09 | +6.86% |
Aug 13, 2024 | $0.80 | $0.74 | -7.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PAVmed Inc (PAVM) report earnings?
PAVmed Inc (PAVM) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is PAVmed Inc (PAVM) earnings time?
PAVmed Inc (PAVM) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PAVM EPS forecast?
PAVM EPS forecast for the fiscal quarter 2025 (Q2) is -0.13.